Citizens raises Pharvaris stock price target to $75 on trial progress
Citizens has increased its price target for Pharvaris B.V. to $75.00 from $74.00, maintaining a Market Outperform rating, due to ongoing trial progress. The company's stock has surged 70% in the past year, and key Phase 3 CHAPTER-3 data is expected this quarter. Pharvaris …